Kaya Holdings (KAYS) Net Income towards Common Stockholders (2011 - 2025)
Kaya Holdings (KAYS) recorded quarterly Net Income towards Common Stockholders of -$8.6 million in Q3 2025, down 242.92% quarter-over-quarter from -$2.5 million in Q2 2025, and down 244.3% on a YoY basis from $6.0 million in Q3 2024.
Kaya Holdings (KAYS) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends
Kaya Holdings' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$8.6 million for Q3 2025.
- In Q3 2025, Net Income towards Common Stockholders fell 244.3% year-over-year to -$8.6 million; the TTM figure through Sep 2025 stood at -$13.9 million (down 336.32% YoY), while the FY2024 annual figure was -$2.2 million, down 235.81% from the prior year.
- Net Income towards Common Stockholders was -$8.6 million for Q3 2025 at Kaya Holdings, down from -$2.5 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $9.2 million in Q2 2021 to a low of -$13.1 million in Q4 2021.
- Historically, Net Income towards Common Stockholders has averaged -$1.1 million across 5 years, with a median of -$1.1 million in 2022.
- The sharpest annual moves came in 2021 and 2024: Net Income towards Common Stockholders jumped 744.03% in 2021, then slumped 1958.97% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$13.1 million in 2021, then jumped by 31.74% to -$9.0 million in 2022, then surged by 100.67% to $60080.0 in 2023, then plunged by 1958.97% to -$1.1 million in 2024, then sank by 669.24% to -$8.6 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$8.6 million (Q3 2025), -$2.5 million (Q2 2025), and -$1.7 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Kaya Holdings | - | - | 5,370.00 | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -2.51 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | -2.50 Mn |
| Jun 30, 2024 | 357,210.00 |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | 60,080.00 |
| Sep 30, 2023 | 702,407.00 |
| Jun 30, 2023 | 598,450.00 |
| Mar 31, 2023 | 67,159.00 |
| Dec 31, 2022 | -8.96 Mn |
| Sep 30, 2022 | 7.41 Mn |
| Jun 30, 2022 | 3.07 Mn |
| Mar 31, 2022 | -1.10 Mn |
| Dec 31, 2021 | -13.13 Mn |
| Sep 30, 2021 | 3.95 Mn |
| Jun 30, 2021 | 9.18 Mn |
| Mar 31, 2021 | -5.52 Mn |
| Dec 31, 2020 | 3.38 Mn |